1. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.
- Author
-
Polverelli N, Hernández-Boluda JC, Czerw T, Barbui T, D'Adda M, Deeg HJ, Ditschkowski M, Harrison C, Kröger NM, Mesa R, Passamonti F, Palandri F, Pemmaraju N, Popat U, Rondelli D, Vannucchi AM, Verstovsek S, Robin M, Colecchia A, Grazioli L, Damiani E, Russo D, Brady J, Patch D, Blamek S, Damaj GL, Hayden P, McLornan DP, and Yakoub-Agha I
- Subjects
- Humans, Splenomegaly etiology, Transplantation Conditioning, Primary Myelofibrosis complications, Primary Myelofibrosis therapy, COVID-19 complications, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute therapy, Thrombosis complications
- Abstract
Splenomegaly is a hallmark of myelofibrosis, a debilitating haematological malignancy for which the only curative option is allogeneic haematopoietic cell transplantation (HCT). Considerable splenic enlargement might be associated with a higher risk of delayed engraftment and graft failure, increased non-relapse mortality, and worse overall survival after HCT as compared with patients without significantly enlarged splenomegaly. Currently, there are no standardised guidelines to assist transplantation physicians in deciding optimal management of splenomegaly before HCT. Therefore, the aim of this Position Paper is to offer a shared position statement on this issue. An international group of haematologists, transplantation physicians, gastroenterologists, surgeons, radiotherapists, and radiologists with experience in the treatment of myelofibrosis contributed to this Position Paper. The key issues addressed by this group included the assessment, prevalence, and clinical significance of splenomegaly, and the need for a therapeutic intervention before HCT for the control of splenomegaly. Specific scenarios, including splanchnic vein thrombosis and COVID-19, are also discussed. All patients with myelofibrosis must have their spleen size assessed before allogeneic HCT. Myelofibrosis patients with splenomegaly measuring 5 cm and larger, particularly when exceeding 15 cm below the left costal margin, or with splenomegaly-related symptoms, could benefit from treatment with the aim of reducing the spleen size before HCT. In the absence of, or loss of, response, patients with increasing spleen size should be evaluated for second-line options, depending on availability, patient fitness, and centre experience. Splanchnic vein thrombosis is not an absolute contraindication for HCT, but a multidisciplinary approach is warranted. Finally, prevention and treatment of COVID-19 should adhere to standard recommendations for immunocompromised patients., Competing Interests: Declaration of interests CH received grants from Novartis and Constellation Pharmaceutical; consulting fees from Keros, Galecto, AOP, and Roche; payment for presentations from Novartis, Celgene, CTI BioPharma, AbbVie, Jansen, Constellation Pharmaceuticals, Galecto, CTI BioPharma, Roche, Geron, Promedior, AbbVie, and AOP Pharma; support for attending meetings from Novartis; participated on advisory boards for Galecto and Keros; and held leadership or fiduciary roles in European Hematology Association, British Society for Haematology, Myeloproliferative Neoplasms Voice, and Blood Cancer UK. NK received research grants from Novartis; consulting fees from Novartis; payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis and Neovii; support for attending meetings and travel from Neovii; participated on a data safety monitoring board or advisory board for Hovon and Novartis; and held leadership or fiduciary roles in other boards, societies, committees or advocacy groups, paid or unpaid, for the European Society for Blood and Marrow Transplantation, German Society for Stem Cell Transplantation and Cellular Therapy, and the German Registry for Stem Cell Transplantation. RM received funding from Celgene, Incyte, AbbVie, Samus, Genotech, Promedior, CTI, Constellation, Mays Cancer Center, and P30 Cancer Center; support grants from National Cancer Institute (grant number CA054174); and consulting fees from Novartis, Sierra Onc, LaJolla, Pharma, and Constellation. NPe received support from the National Institutes of Health, National Cancer Institute (award number P30 CA016672); grants from Affymetrix, US Department of Defence, and SagerStrong foundation; royalties from Karger Publishers; consulting fees from Pacylex Pharmaceuticals, ImmunoGen, Bristol-Myers Squibb, Blueprint Medicines, Clearview Healthcare Partners, Astellas Pharma US, and Protagonist Therapeutics; honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Diagnostics, Blueprint Medicines, DAVA Oncology, Springer Science + Business Media, Aptitude Health, and CareDx; support for attending meetings from Stemline Therapeutics, Celgene, MustangBio, DAVA oncology, AbbVie; participated on a data safety monitoring board and advisory board for ASCO Leukemia Advisory Panel; held leadership or fiduciary role in other boards, societies, committees or advocacy groups, paid or unpaid for by American Society of Hematology Communications Committee, Dan's House of Hope, and HemOnc Times/Oncology Times; and received equipment, materials, drugs, medical writing support, gifts, or other services from Novartis, Stemline Therapeutics, Samus Therapeutics, AbbVie, CEllectis, Affymetrix, Daiichi Sankyo, and Plexxikon. UP received research funding from Bayer, Novartis, AbbVie, and Incyte. AMV participated in advisory boards for Novartis; and provided consulting services for Novartis. IY-A received honoraria from Novartis. All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF